Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immunic ( (IMUX) ) has shared an update.
On May 28, 2025, Immunic, Inc. announced the commencement of an underwritten public offering of pre-funded warrants and Series A and B warrants to purchase shares of common stock. The proceeds from this offering are intended to fund clinical trials and general corporate purposes. Additionally, the company published an updated corporate presentation on its website, revealing extended data from its phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis, highlighting its ongoing efforts in drug development for chronic inflammatory and autoimmune diseases.
The most recent analyst rating on (IMUX) stock is a Buy with a $1.20 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.
Spark’s Take on IMUX Stock
According to Spark, TipRanks’ AI Analyst, IMUX is a Underperform.
Immunic’s overall stock score is primarily impacted by its challenging financial performance, marked by high R&D costs without corresponding revenue. Technical analysis shows moderate short-term bullish signals, but long-term valuation remains unattractive due to negative earnings and lack of dividends. The company’s ability to improve its financial position relies heavily on successful product commercialization or securing additional funding.
To see Spark’s full report on IMUX stock, click here.
More about Immunic
Immunic, Inc. is a biotechnology company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Its lead development program, vidofludimus calcium, is in phase 3 clinical trials for relapsing multiple sclerosis and has shown therapeutic activity in earlier trials for multiple sclerosis. The company is also working on other drug candidates targeting gastrointestinal diseases.
Average Trading Volume: 849,625
Technical Sentiment Signal: Sell
Current Market Cap: $85.28M
For a thorough assessment of IMUX stock, go to TipRanks’ Stock Analysis page.